Catechol-O-methyltransferase Val158Met polymorphism is associated with somatosensory amplification and nocebo responses.
A large number of unwanted adverse events and symptoms reported by patients in clinical trials are not caused by the drug provided, since most of adverse events also occur in corresponding placebo groups. These nocebo effects also play a major role in drug discontinuation in clinical practice, negat...
| Päätekijät: | , , , , , , , , |
|---|---|
| Aineistotyyppi: | Artikkeli |
| Kieli: | English |
| Julkaistu: |
Public Library of Science (PLoS)
2014-01-01
|
| Sarja: | PLoS ONE |
| Linkit: | http://europepmc.org/articles/PMC4164653?pdf=render |